Tumor‑Infiltrating Lymphocyte Therapy
Feb 20, 2026
Tumor‑Infiltrating Lymphocyte (TIL) Therapies: Redefining Cell Therapy for Solid Tumors
Summary TIL therapy marks a major shift in solid-tumor immunotherapy, offering an effective approach where CAR-T strategies have struggled, broadening options beyond PD-1 and BRAF/MEK inhibitors for metastatic melanoma, and driving extensive clinical evaluation across NSCLC, HNSCC, CRC, pancreatic, prosta...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
